Industry
Biotechnology
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Loading...
Open
0.91
Mkt cap
3.9M
Volume
141K
High
0.93
P/E Ratio
-0.75
52-wk high
4.50
Low
0.83
Div yield
N/A
52-wk low
0.83
Portfolio Pulse from Benzinga Newsdesk
September 12, 2023 | 12:52 pm
Portfolio Pulse from Lara Goldstein
September 05, 2023 | 2:08 pm
Portfolio Pulse from Benzinga Newsdesk
August 31, 2023 | 11:48 am
Portfolio Pulse from richadhand@benzinga.com
August 28, 2023 | 8:51 am
Portfolio Pulse from Lara Goldstein
August 14, 2023 | 1:47 pm
Portfolio Pulse from Benzinga Newsdesk
August 10, 2023 | 12:52 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.